Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma
NCT02911142Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2017
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in primary effusion lymphoma (PEL) and HHV8-associated diffuse large B-cell lymphoma (HHV8-DLBCL), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 6 weeks and Overall Survival at 5 years. Started Jul 2017; status: active, not recruiting.
02
Drugs
lenalidomide
03
Conditions
primary effusion lymphoma (PEL)HHV8-associated diffuse large B-cell lymphoma (HHV8-DLBCL)
Beyond the preview
Go deeper on NCT02911142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911142.